https://www.live-feeds.com/feed/fda-approves-new-blood-test-for-alzheimer-s-diseaseContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-approves-new-blood-test-for-alzheimer-s-diseasehttps://www.live-feeds.com/feed/fda-approves-new-blood-test-for-alzheimer-s-disease#u51820Sat, 29 Aug 2026 13:45:32 +0000The US FDA has cleared the Elecsys pTau-217 blood test, a diagnostic tool developed by Roche and Eli Lilly to detect Alzheimer's disease pathology. Labcorp will provide the single-biomarker test in specialty and primary care settings for adults 55 and older exhibiting cognitive decline. The test uses a single vial of blood to identify biomarkers, offering a less invasive alternative to traditional diagnostic procedures. Early detection is critical because current FDA-approved prescriptions are most effective when administered during the earliest stages of the disease.Why it mattersTraditi https://www.live-feeds.com/feed/fda-approves-new-blood-test-for-alzheimer-s-diseasehttps://www.live-feeds.com/feed/fda-approves-new-blood-test-for-alzheimer-s-disease#u50596Fri, 28 Aug 2026 07:36:24 +0000Labcorp will offer the Elecsys pTau-217 blood test in primary and specialty care settings following US FDA clearance. Developed by Roche and Eli Lilly, the single-biomarker test detects Alzheimer's disease pathology using a blood sample rather than invasive methods. The diagnostic is intended for adults aged 55 and older who show signs of cognitive decline. By identifying biomarkers in a single vial of blood, the tool helps clinicians detect the disease earlier and provides a less invasive alternative to traditional diagnostic procedures.Why it mattersEarly detection of Alzheimer's i https://www.live-feeds.com/feed/fda-approves-new-blood-test-for-alzheimer-s-diseasehttps://www.live-feeds.com/feed/fda-approves-new-blood-test-for-alzheimer-s-disease#u48596Wed, 26 Aug 2026 02:10:48 +0000The US Food and Drug Administration approved a first-of-its-kind biomarker blood test developed by Roche and Eli Lilly to detect signs of Alzheimer's disease. The test is intended for adults aged 55 and older who are already experiencing cognitive decline. Roche announced the approval on August 24. This diagnostic tool allows clinicians to identify Alzheimer's markers through a blood sample rather than more invasive methods.Why it mattersEarly and accurate detection of Alzheimer's is critical for initiating treatment and planning care. Traditional diagnostics often require expen